Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Karmiel
21000
Tel: 972-4-988-9488
Fax: 972-4-988-9489
Website: http://www.protalix.com/
Email: info@protalix.com
301 articles about Protalix Biotherapeutics, Inc.
-
Protalix Biotherapeutics to Present at the Opening Plenary Session of the Plant and Animal Genome XVII Conference
1/5/2009
-
Protalix Biotherapeutics Announces First Patient Enrolled in Open-Label, Switchover Trial of prGCD for the Treatment of Gaucher Disease
12/19/2008
-
Protalix Biotherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease
12/2/2008
-
Protalix Biotherapeutics to Present at the Piper Jaffray 20th Annual Health Care Conference
11/25/2008
-
Protalix Biotherapeutics to Present at Oppenheimer Annual Healthcare Conference and at Barclays Capital Small & Mid-Cap Health Care Conference
10/28/2008
-
Protalix Biotherapeutics Provides Enrollment Update for the Phase III Clinical Trial of prGCD
9/22/2008
-
Protalix Biotherapeutics to Present at the UBS Warburg Global Life Sciences Conference
9/18/2008
-
Protalix Biotherapeutics Sets Record Date for Annual Meeting of Shareholders
9/9/2008
-
Protalix Biotherapeutics to Present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference
7/31/2008
-
Protalix Biotherapeutics Joins the Russell MicrocapTM Index
7/1/2008
-
Protalix Biotherapeutics to Initiate an Open-Label Extension Study for the Phase III Clinical Trial of prGCD
6/3/2008
-
Protalix Biotherapeutics to Present at Three International Healthcare Conferences
5/23/2008
-
Protalix Biotherapeutics Receives Research Grant from the Office of the Chief Scientist of Israel's Ministry of Industry and Trade
4/8/2008
-
Protalix Biotherapeutics's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
4/3/2008
-
Protalix Biotherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
2/12/2008
-
Protalix Biotherapeutics Extends Research Agreement With Yissum Ltd. Based on Promising Acetylcholinesterase Program Results in Animal Study
1/22/2008
-
Protalix Biotherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
1/14/2008
-
Protalix Biotherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
12/3/2007
-
Protalix Biotherapeutics Announces Resignation of Board Members
12/3/2007
-
Protalix Biotherapeutics Sets Record Date for Annual Meeting of Shareholders
11/29/2007